Skip to main content
Discovery of Aficamten (CK-274): Next-in-class Cardiac myosin inhibitor (CMI) for obstructive Hypertrophic Cardiomyopathy (oHCM)
Cardiac Myosin Inhibitor, CK-586, Minimally Reduces Systolic Function and Ameliorates Obstruction in Feline Hypertrophic Cardiomyopathy
Fast Skeletal Muscle Troponin Activator CK-4015089 Improves Muscle Function in a FSHD Mouse Model with Muscle Weakness
Pharmacokinetics, Excretion, and Metabolism of [14C]Aficamten Following Single Oral Dose Administration to Rats
Preclinical Pharmacokinetics of CK-4021586, a Novel Inhibitor of Cardiac Myosin, and Prediction of Human Pharmacokinetics
Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats
Acute Treatment With Aficamten Rescues Contractile Function in a Myopod® Engineered Heart Tissue Model of Hypertrophic Cardiomyopathy
Preclinical Characterization of CK-4021586, a New Class of Cardiac Myosin Inhibitors for the Treatment of Hypertrophic Cardiomyopathy
Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy
Pharmacokinetics of a Single Dose of Aficamten (CK-274) on Cardiac Contractility in a A31P MYBPC3 Hypertrophic Cardiomyopathy Cat Model